期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拓扑替康在小细胞肺癌中的应用 被引量：4

The application of topotecan in treatment of small cell lung cancer(SCLC)
下载PDF
导出
摘要 小细胞肺癌 (SCLC)治疗新药盐酸拓扑替康 (topotecan)属喜树碱类 ,为拓扑异构酶Ⅰ抑制剂 ,它能导致DNA复制叉断裂 ,该作用方式决定其不易产生耐药性。其剂量限制毒性 (DLT)为中性粒细胞减少和腹泻 ,肝肾功能下降会降低最大耐受剂量 (MTD)。拓扑替康对SCLC最常用的有效剂量是 1.5mg·m-2 ·d-1× 5d。临床前实验发现 ,拓扑替康对耐药SCLC细胞株NCL H82rasH的杀瘤作用比单独使用顺铂的作用强 2 5 0倍 ,与顺铂或VP16有协同作用。临床试验结果亦证明 ,拓扑替康是有效的一线及二线抗肿瘤药 ,尤其对于既往化疗敏感而又复发处于进展期的患者及对颅内转移的症状和体征有明显的缓解作用。 Topotecan,a new agent for SCLC treatment,is a topo is onerase inhibitor.It can induce the fragmentation of DNA replication fork,theref ore it is not easy to produce drug resistance.The dose limiting toxicity(DLT) o f it was neutropenia and diarrhea.Its maximum tolerance dose(MTD) may be reduced by elevated liver or kidney function.The usual dose for SCLC treatment is 1.5 m g·m -2 ·d -1 ×5d.Pre clinical trials indicated that the cancer killi ng effect of topotecan is as potent as 250 times of cisplatin for drug resistanc e cancer strain of NCL H82rasH,and it has a synergetic effect with cisplatin or VP16.Clinical trials indicated that topotecan is an anticancer agent of first o r second choice,especially for patients who are sensitive to anticancer agent in the past and replicated now.The agent can significantly relief the symptoms and signs of brain metastasis of lung cancer.
作者 张力 宁晓红 毕洪霞 李龙芸
机构地区 中国医学科学院中国协和医科大学北京协和医院呼吸内科
出处 《中国新药杂志》 CAS CSCD 北大核心 2001年第10期743-746,共4页 Chinese Journal of New Drugs
关键词 拓扑替康 小细胞肺癌 拓扑异构酶Ⅰ抑制剂 topotecan Small cell lung cancer topoisonerase inhi bitor
分类号 R734.2 [医药卫生—肿瘤] R979.1 [医药卫生—药品]
  • 相关文献

参考文献9

  • 1李志勇,郭勇.抗癌药——喜树碱衍生物[J].中国新药杂志,2000,9(9):598-601. 被引量：7
  • 2Dennis MJ, Beijnen JH. An Overview of the clinical pharmacology of topotecan[J]. Semin Oncol, 1997, 24(Suppl 5) :S12 - S18.
  • 3Rowinsky EK, Grochow LB, Bendricks CB, et al. Phase I and pharmacologic study of topotacan: a novel topoisomerase I inhibitor [J] .J Clin Oncol, 1992,10(4) :647 - 656.
  • 4Heron JF.Topotecan:an Oncologist's View[J]. The Oncologist,1998, 3(6) :390 - 402.
  • 5Arbuck SG-, Takimoto CH. An overview of topoisomeraseI-targeting agents[J]. Semin Oncol, 1998,135(Suppl 4) :53 - S12.
  • 6McCabe FL, Johnson RK. Comparative activity of oral and parenteral topotecan in murine tumor models: Efficacy of oral topotecan[J]. Cancer Invest, 1994,12(3) :308 - 313.
  • 7Schiller JH, Kim K, Hutson P. Phase Ⅱ study of topotecan in patients with extensive-stage small-cell carcinoma of the lung[J]. J Clin Oncol, 1996, 14(8) :2345 - 2352.
  • 8Jett JR, Day R, Levitt M. Topotecan and paclitaxel in extensive stage small celllung cancer(ED-SCLC)patients without prior therapy[J]. Lung Cancer, 1997, 18(Suppl 1 ):38a
  • 9Pawel J, Schiller JH, Shepherd FA. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J] .J Clin Oncol, 1999, 17(2) :658 -667.

二级参考文献13

  • 1RowePM.Camptothecin:newenthusiasmforanolddrug[J].Lancet,1995,347∶892-896.[3]GiovanellaBC,StehlinJS,WallME,etal.DNAtopoisomeraseItargetchemotherapyofhumancoloncancerxenografts[J].Science,1989,246∶1046-1050.
  • 2RowinskyEK,GrochowLB,HendricksCB,etal.PhaseIandpharmacologicstudyoftopotecan:anoveltopoisomeraseIinhibitor[J].JClinOncol,1992,10∶647-656.
  • 3SchillerJH,KimK,JohnsonD.PhaseⅡstudyoftopotecaninextensivestagesmallcelllungcancer[J].ProcAmSocClinOncol,1994,13∶330.
  • 4RobertF,WheelerRH,MolthropDC,etal.PhaseⅡstudyoftopotecaninadvancedheadandneckcancer:Identificationofanactivenewagent[J].ProcAmSocClinOncol,1994,13∶905.
  • 5EisenhauerEA,WainmanN,BoosG,etal.PhaseⅡtrialsoftopotecaninpatients(pts)withmalignantgliomaandsofttissuesarcoma[J].ProcAmSocClinOncol,1994,13∶175.
  • 6VerweijJ,LundB,BeijnenJ,etal.PhaseIandpharmacokineticsstudyoftopotecan,anewtopoisomeraseIinhibitor[J].AnnOncol,1993,4∶673-678.
  • 7MillerAA,HargisJB,LilenbaumRC,etal.PhaseIstudyoftopotecanandcisplatininpatientswithadvancedcancer:acancerandleukemiagroupBstudy[J].JClinOncol,1994,12∶2743-2750.
  • 8AbigergesD,ChabotGG,ArmandJP,etal.PhaseIandpharmacologicstudiesofthecamptothecinanalogueirinotecanadministeredevery3weeksincancerpatients[J].JClinOncol,1995,13∶210-221.
  • 9AbigergesD,ArmandJP,ChabotGG,etal.Irinotecan(CPT-11)high-doseescalationusingintensivehigh-doseloperamidetocontroldiarrhea[J].JNatlCancerInst,1994,86∶446-449.
  • 10ShimadaY,RougierP,PitotH,etal.EfficacyofCPT-11(irinotecan)andasingleagentinmetastaticcolorectalcancer[J].EurJCancer,1996,32(ASuppl3)∶S13-S23.

共引文献6

同被引文献23

  • 1Grant SC,Gralla RJ,Kriss MG,et al.Single agent chem-otherapy trial in small cell lung cancer,1970 to 1990:the case for studies in previously treated patients[J].J Clin Oncol,1992,10:484.
  • 2Albain KS,Crowley JJ,Hutchins L,et al.Predictors of survival following relapse or progression of small cell lung cancer[J].Cancer,1993,72:1184.
  • 3Von Pawel J,Schiller JH,Shepherd FA,et al.Topotecan versus cyclophosphamide,doxorubicin,and vincristine for the treatment of recurrent small cell lung cancer[J].J Clin Oncol,1999,17:658.
  • 4Gizawy EL,Hedaya MA.Comparative brain tissue distribution of camptothecin and topotecan in the rat[J].Cancer Chemother Pharmacol,1999,43(5):364.
  • 5Andrea A, Christan M, Channa D, et al. European organization for research and treatment of caner( EORTC)08957 phase Ⅱ study of topoteacan in combination with cisplatin as second-line treatment of refreactory and sensitive small cell lung cancer [ J ] . Clin Cancer Res,2003,9( 1 ) : 143 - 150.
  • 6Schiller JH,Kim K, ,Hutson P,et al. Phase Ⅱ　 study of topoteacan in patients with extensive stage small cell carcinoma of the lung an eastern cooperative oncology group trial [ J ]. J Clin Oncol, 1996,14(8) : 2345 - 2352.
  • 7Schiller JH.Lung cancer: therapeutic modalities and cytoprotection [J].Lung, 1998, 176 (3): 145-164.
  • 8Gizawy EL, Hedaya MA.Comparative brain tissue distribution of campothecin and topotecan in the rat [ J ] .Cancer Chemother Pharmacol,1999. 43 (5) : 364 - 370.
  • 9Ardizzoni A,et al.Topotecan,a new active drug in secondline treatment of small-cell lung cancer:a phase 11 study in patients with refractory and sensitive disease[J].J Clin Oncol,1997,15(5):2090-2096.
  • 10Brackl WM, Lampert S, Zirlik S, el al. Drug therapy for small-cell lung cancer(SCLC) new molecular strategies for therapy[J]. Pneumologie, 2008, 62(1): 23-30.

引证文献4

二级引证文献2

中国新药杂志
2001年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部